Fox Foundation Backs Novel Drug Targeting Brain's Overlooked 'Cleanup Crew'

PRINCETON, N.J. – June 18, 2026 – In the relentless search for a therapy that can slow or stop Parkinson's disease, the spotlight often falls on the brain's neurons. But a new grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) is illuminating a different path, one that focuses on the brain's crucial but often-overlooked support system.

iQure Pharma, a clinical-stage biotech firm, announced today it has received funding from MJFF's prestigious Parkinson's Disease Therapeutics Pipeline Program. The grant will accelerate preclinical research into iQ-007, a first-in-class drug candidate designed not to act on neurons directly, but to empower the brain's cellular 'cleanup crew'—the astrocytes.

This move signals a significant validation for a novel strategy in the fight against neurodegeneration. By targeting a fundamental mechanism of cellular maintenance, iQure aims to do what no current Parkinson's therapy can: address the underlying cascade of damage that drives the disease forward.

A Bet on Restoring Balance

The grant will fund studies to establish a clear link between the drug's mechanism and its functional effects in disease-relevant models of Parkinson's. A key goal is to identify a clinical biomarker—a measurable signpost in the body—that could help predict which patients are most likely to benefit from this new approach. This is a critical step in moving from broad-stroke treatments to personalized medicine in neurology.

"This grant enables us to further establish the mechanistic link between extracellular glutamate regulation and functional outcomes in Parkinson's disease," said Pawel Zolnierczyk, Chief Executive Officer of iQure Pharma. "Our lead asset, iQ-007, is the first clinical-stage EAAT2 modulator. Through this work, we continue to build the scientific foundation positioning EAAT2 modulation as a therapeutic approach across multiple CNS disorders."

The program is a heavyweight collaboration, bringing together iQure's internal team, the renowned contract research organization Atuka Inc., and the academic expertise of Associate Professor Laura Civiero from the University of Padova, an international expert on the role of the astroglial system in Parkinson's.

For MJFF, the investment aligns with its mission to de-risk and accelerate promising science. "EAAT2 modulation represents an emerging area of interest in Parkinson's research, and studies like this aim to generate translational data that may help inform future therapeutic development," noted Jessica Tome Garcia, a Lead Scientific Program Manager at the foundation.

The 'Excitotoxicity' Problem

To understand the significance of iQure's approach, we have to look beyond the familiar narrative of dopamine loss in Parkinson's. The brain operates on a delicate chemical balance. Its primary excitatory neurotransmitter, glutamate, is essential for learning and memory. But in excess, it becomes a potent toxin.

When glutamate floods the space between neurons and isn't cleared away efficiently, it overstimulates them, causing a destructive process called 'excitotoxicity.' This toxic feedback loop of overstimulation leads to neuronal damage and death, a core feature not just in Parkinson's but also in ALS, epilepsy, and other chronic brain disorders.

This is where astrocytes come in. These star-shaped glial cells, once considered mere structural support for neurons, are now understood to be active managers of the brain's environment. One of their most critical jobs is to clear excess glutamate from the synapse using a specialized protein transporter called EAAT2. In many neurodegenerative diseases, this EAAT2 transporter is dysfunctional or its levels are depleted. The cleanup crew is overwhelmed, and excitotoxicity takes hold.

Instead of trying to block the downstream effects of glutamate, iQure's strategy is to fix the problem at its source by enhancing the function of the EAAT2 transporter itself. Their drug, iQ-007, is a positive allosteric modulator (PAM), meaning it doesn't turn the transporter on or off but rather fine-tunes its activity, boosting its natural ability to clear glutamate. It’s less like a sledgehammer and more like a sophisticated repair job on the brain's own maintenance system.

A Platform for Brain Health

iQ-007 is the first clinical candidate to emerge from iQure’s astrocyte-centered platform. The orally available small molecule, developed at Poland's Jagiellonian University, is already in Phase 1 clinical trials for treatment-resistant epilepsy, another condition driven by neuronal hyperexcitability. With promising preclinical data across multiple disease models, the company sees a broad horizon for its technology.

The MJFF grant for Parkinson's research is a strategic expansion, applying the same core principle of restoring glutamate homeostasis to a different, devastating disease. The company is also advancing preclinical work for its potential use in ALS and migraine, positioning the modulation of EAAT2 not as a single-shot therapy, but as a potential platform for treating a host of CNS conditions rooted in a common pathology.

This strategic breadth is built on a solid foundation. The company secured a U.S. patent for iQ-007 in September 2025, protecting its composition and use, a crucial step for any clinical-stage company navigating the long road of drug development.

Hope for a New Therapeutic Era

For the millions of people living with Parkinson's worldwide, the therapeutic landscape remains frustratingly limited. Current treatments primarily manage motor symptoms by replacing dopamine, but they do not stop the relentless progression of the disease. The patient community and advocacy groups like the Parkinson's Foundation have been vocal about the urgent need for disease-modifying therapies that can protect the brain and preserve function.

The backing of a highly focused and influential organization like MJFF provides more than just financial resources; it confers a level of scientific validation that can attract further investment and talent. It signals that this novel approach, targeting the brain's fundamental housekeeping, is not a fringe idea but a serious contender for the next generation of neurological drugs.

By moving beyond the neuron and focusing on the ecosystem that keeps it healthy, iQure Pharma and its collaborators are opening a new front in the war against neurodegeneration. While the path through clinical trials is long and uncertain, this grant marks a pivotal moment, affirming that restoring the brain's own protective mechanisms may be one of the most powerful strategies we have.